AKT1 and cancer: Given that the PI3K-AKT pathway can target ETS1 to promote tumor progression in multiple cancers, and ETS1 has been demonstrated to drive epithelial-mesenchymal transition (EMT), this study hypothesizes that EFNA4 may inhibit the PI3K-AKT signaling axis, thereby counteracting ETS1-mediated EMT.